Regulus Therapeutics

Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The firm is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded on September 5, 2007 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The firm is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded in 2007 and is headquartered in San Diego, CA.

Allena Pharmaceuticals

Billionaire investor Steven Cohen (Trades, Portfolio) disclosed earlier this week his firm, Point72 Asset Management, established a 14.37% stake in Regulus Therapeutics Inc. (NASDAQ:RGLS) and a 7.96% position in Allena Pharmaceuticals Inc. (NASDAQ:ALNA) on Dec. 4.

Steven Cohen Boots Health Care Exposure With 2 Biotech Stocks

Investors need to pay close attention to Regulus Therapeutics (RGLS) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Regulus Therapeutics (RGLS) Stock?

LA JOLLA, Calif., Dec. 8, 2020 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the closing of its previously announced private placement of equity....

Regulus Therapeutics Announces Closing of $19.4 Million Private Placement of Equity

Bio-Techne

MINNEAPOLIS, Dec. 2, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and Regulus Therapeutics (NASDAQ: RGLS) announced a collaboration to support Regulus with biomarker analysis for the clinical development of RGLS4326, an Autosomal Dominant Polycystic Kidney Disease (ADPKD)...

Regulus Therapeutics Collaborates With Bio-Techne For Biomarker Development

Regulus (RGLS) delivered earnings and revenue surprises of 80.00% and 880.39%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Regulus (RGLS) Reports Q3 Loss, Tops Revenue Estimates

LA JOLLA, Calif., Nov. 5, 2020 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results for the third quarter...

Regulus Therapeutics Reports Third Quarter 2020 Financial Results and Recent Updates

Regulus (RGLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Regulus (RGLS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

LA JOLLA, Calif., Nov. 2, 2020 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it has achieved the remaining $5 million milestone associated...

Regulus Therapeutics Announces Achievement of Interim Enrollment Milestone Under Collaboration with Sanofi

LA JOLLA, Calif., Oct. 15, 2020 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced initiation of dosing in its Phase 1b...

Regulus Therapeutics Announces First Patient Dosed in Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

LA JOLLA, Calif., Oct. 13, 2020 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS) (the "Company" or "Regulus"), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced receipt of a total of $5 million in...

Regulus Therapeutics Announces Receipt of $5 Million Milestone and Material Payments from Sanofi

LA JOLLA, Calif., Sept. 11, 2020 /PRNewswire/ -- Regulus Therapeutics Inc.

Regulus Therapeutics to Present at the H.C. Wainwright 22nd Annual Virtual Global Investment Conference

LA JOLLA, Calif., Sept. 3, 2020 /PRNewswire/ -- Regulus Therapeutics Inc.

Regulus Therapeutics to Present at the 2020 Wells Fargo Virtual Healthcare Conference

LA JOLLA, Calif., Aug. 31, 2020 /PRNewswire/ -- Regulus Therapeutics Inc.

Regulus Therapeutics Announces Restructuring of Sanofi and Oxford Loan Agreements

Regulus (RGLS) delivered earnings and revenue surprises of -9.52% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Regulus (RGLS) Reports Q2 Loss, Lags Revenue Estimates

LA JOLLA, Calif., Aug. 13, 2020 /PRNewswire/ -- Regulus Therapeutics Inc.

Regulus Therapeutics Reports Second Quarter 2020 Financial Results and Recent Updates

Regulus (RGLS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

LA JOLLA, Calif., Aug. 6, 2020 /PRNewswire/ -- Regulus Therapeutics Inc.

Regulus Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

LA JOLLA, Calif., Aug. 3, 2020 /PRNewswire/ -- Regulus Therapeutics Inc.

Regulus Therapeutics Appoints Denis Drygin, Ph.D., as Chief Scientific Officer

LA JOLLA, Calif., July 29, 2020 /PRNewswire/ -- Regulus Therapeutics Inc.

Regulus Therapeutics Announces FDA Orphan Drug Designation of RGLS4326 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

LA JOLLA, Calif., July 22, 2020 /PRNewswire/ -- Regulus Therapeutics Inc.

Regulus Therapeutics Completes Dosing in Phase 1 Multiple Ascending Dose Study of RGLS4326 in Healthy Volunteers for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

LA JOLLA, Calif., May 14, 2020 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results for the first quarter...

Regulus Therapeutics Reports First Quarter 2020 Financial Results and Recent Updates

Regulus (RGLS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News for Regulus Therapeutics Stock (RGLS)